Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2007 5
2008 1
2009 5
2010 14
2011 11
2012 12
2013 8
2014 8
2015 7
2016 6
2017 3
2018 6
2019 10
2020 10
2021 15
2022 11
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

117 results
Results by year
Filters applied: . Clear all
Page 1
Patient-Derived Organoids for Precision Cancer Immunotherapy.
Grönholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Grönholm M, et al. Among authors: cerullo v. Cancer Res. 2021 Jun 15;81(12):3149-3155. doi: 10.1158/0008-5472.CAN-20-4026. Epub 2021 Mar 9. Cancer Res. 2021. PMID: 33687948 Review.
Pathogens: Our Allies against Cancer?
Buonaguro L, Cerullo V. Buonaguro L, et al. Among authors: cerullo v. Mol Ther. 2021 Jan 6;29(1):10-12. doi: 10.1016/j.ymthe.2020.12.005. Epub 2020 Dec 5. Mol Ther. 2021. PMID: 33308440 Free PMC article. Review. No abstract available.
Oncolytic Adenoviruses for Cancer Therapy.
Tripodi L, Vitale M, Cerullo V, Pastore L. Tripodi L, et al. Among authors: cerullo v. Int J Mol Sci. 2021 Mar 3;22(5):2517. doi: 10.3390/ijms22052517. Int J Mol Sci. 2021. PMID: 33802281 Free PMC article. Review.
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F, Ylösmäki E, Chiaro J, Giannoula Y, Long M, Fusciello M, Feola S, Martins B, Feodoroff M, Antignani G, Russo S, Kari O, Lee M, Järvinen P, Nisen H, Kreutzman A, Leusen J, Mustjoki S, McWilliams TG, Grönholm M, Cerullo V. Hamdan F, et al. Among authors: cerullo v. J Immunother Cancer. 2021 Aug;9(8):e003000. doi: 10.1136/jitc-2021-003000. J Immunother Cancer. 2021. PMID: 34362830 Free PMC article.
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Ylösmäki E, Antignani G, Chiaro J, Hamdan F, Feodoroff M, Grönholm M, Cerullo V. Feola S, et al. Among authors: cerullo v. Front Immunol. 2022 Apr 14;13:826164. doi: 10.3389/fimmu.2022.826164. eCollection 2022. Front Immunol. 2022. PMID: 35493448 Free PMC article.
Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.
Serra A, Fratello M, Federico A, Ojha R, Provenzani R, Tasnadi E, Cattelani L, Del Giudice G, Kinaret PAS, Saarimäki LA, Pavel A, Kuivanen S, Cerullo V, Vapalahti O, Horvath P, Lieto AD, Yli-Kauhaluoma J, Balistreri G, Greco D. Serra A, et al. Among authors: cerullo v. Brief Bioinform. 2022 Jan 17;23(1):bbab507. doi: 10.1093/bib/bbab507. Brief Bioinform. 2022. PMID: 34962256 Free PMC article.
117 results